CHICAGODrugs designed to unleash the bodys own immune system against cancer are significantly prolonging the lives of some people with hardtotreat forms of the deadly disease The latest evidence Patients with the skin cancer melanoma who received a combination of two BristolMyers Squibb Co immunotherapies in a clinical trial lived an average of more than three years researchers reported Monday In another study about  of advanced melanoma patients receiving a Merck  Co immunotherapy were still alive after
  